Radnor Capital Management LLC Acquires New Position in Illumina, Inc. $ILMN

Key Points

• Radnor Capital Management LLC invested approximately $2.08 million in Illumina, acquiring 21,760 shares during the second quarter.
• Several hedge funds have increased their positions in Illumina, with notable increases from Tidal Investments LLC, up 740.3%, and GTS Securities LLC, up 7,215.2%.
• Illumina reported a net margin of 29.36% in its latest earnings, despite a year-over-year revenue decrease of 4.8%.

Radnor Capital Management LLC purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 21,760 shares of the life sciences company's stock, valued at approximately $2,076,000.

A number of other institutional investors have also made changes to their positions in ILMN. Moors & Cabot Inc. boosted its position in Illumina by 2.5% during the first quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company's stock valued at $465,000 after acquiring an additional 145 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. grew its position in shares of Illumina by 3.0% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,604 shares of the life sciences company's stock valued at $445,000 after acquiring an additional 164 shares during the period. Nissay Asset Management Corp Japan ADV grew its position in shares of Illumina by 0.9% during the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 22,362 shares of the life sciences company's stock valued at $1,774,000 after acquiring an additional 207 shares during the period. Probity Advisors Inc. boosted its holdings in Illumina by 12.2% in the 4th quarter. Probity Advisors Inc. now owns 2,054 shares of the life sciences company's stock worth $274,000 after buying an additional 224 shares during the period. Finally, Rise Advisors LLC lifted its stake in Illumina by 173.6% in the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company's stock worth $28,000 after purchasing an additional 224 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ILMN has been the topic of a number of recent analyst reports. Canaccord Genuity Group raised their price target on shares of Illumina from $99.00 to $105.00 and gave the stock a "hold" rating in a report on Friday, August 1st. Stephens set a $110.00 target price on shares of Illumina and gave the company an "overweight" rating in a research note on Monday, August 4th. Daiwa Capital Markets downgraded shares of Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 price objective on the stock. in a research report on Tuesday, August 12th. Daiwa America lowered shares of Illumina from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 12th. Finally, Scotiabank cut shares of Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 price target on the stock. in a research report on Friday, July 11th. Six research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $123.06.

Illumina Stock Performance

Shares of ILMN stock traded down $0.28 during trading hours on Friday, hitting $102.75. 3,621,712 shares of the company were exchanged, compared to its average volume of 1,309,960. The firm has a fifty day simple moving average of $99.78 and a 200 day simple moving average of $89.06. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66. The stock has a market capitalization of $15.79 billion, a price-to-earnings ratio of 13.01, a P/E/G ratio of 2.31 and a beta of 1.43.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.17. The firm had revenue of $1.06 billion for the quarter, compared to analysts' expectations of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company's revenue for the quarter was down 4.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.